The weekly litigation news digest is live. Subscribe now

IP Verse

Risperidone Sustained Release Microsphere Composition - EP3566696

The patent EP3566696 was granted to Geneora Pharma Shijiazhuang on Oct 7, 2020. The application was originally filed on Apr 10, 2012 under application number EP19176691A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3566696

GENEORA PHARMA SHIJIAZHUANG
Application Number
EP19176691A
Filing Date
Apr 10, 2012
Status
Opposition Rejected
Feb 10, 2023
Publication Date
Oct 7, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ALKERMES PHARMA IRELANDJul 7, 2021ATKINS -

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONCN101653422
DESCRIPTIONCN1137756
OPPOSITIONCN101653422
OPPOSITIONEP0058481
OPPOSITIONWO2008142153

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents